Development of transgenic mice that inducibly express an active form of c‐Src in the epidermis
暂无分享,去创建一个
D. Roop | Takashi Matsumoto | K. Kiguchi | J. DiGiovanni | S. Carbajal | L. Ruffino | Jianghong Jiang | Xiao-Jing Wang | L. Beltrán
[1] J. Clifford,et al. Epidermal Growth Factor Receptor-Mediated Activation of Stat3 during Multistage Skin Carcinogenesis , 2004, Cancer Research.
[2] Takashi Matsumoto,et al. Targeted expression of c-Src in epidermal basal cells leads to enhanced skin tumor promotion, malignant progression, and metastasis. , 2003, Cancer research.
[3] Hua Yu,et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth , 2002, Oncogene.
[4] Takashi Matsumoto,et al. Overexpression of a constitutively active form of c‐src in skin epidermis increases sensitivity to tumor promotion by 12‐O‐tetradecanoylphorbol‐13‐acetate , 2002, Molecular carcinogenesis.
[5] D. Roop,et al. K14‐GLp65 transactivator induces transgene expression in embryonic epidermis , 2002, Genesis.
[6] B. Weeks,et al. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. , 2001, Cancer research.
[7] J. Turkson,et al. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling , 2000, Oncogene.
[8] J. Grandis,et al. Epidermal Growth Factor Receptor–Mediated Stat3 Signaling Blocks Apoptosis in Head and Neck Cancer , 2000, The Laryngoscope.
[9] K. Mokbel,et al. The effect of surgical wounding on tumour development. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[10] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[11] R. Jove,et al. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.
[12] B. O’Malley,et al. Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Parsons,et al. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[14] B. O’Malley,et al. Adenovirus-mediated regulable target gene expression in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Darnell,et al. Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.
[16] H. Friess,et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. , 1998, Biochemical and biophysical research communications.
[17] J. Jorcano,et al. Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter , 1998, Molecular carcinogenesis.
[18] Y. Wang,et al. Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator , 1997, Gene Therapy.
[19] D. Bol,et al. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice , 1997, Oncogene.
[20] J. DiGiovanni,et al. Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion , 1997, Oncogene.
[21] D. Nathans,et al. In vitro activation of Stat3 by epidermal growth factor receptor kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] M. T. Brown,et al. Regulation, substrates and functions of src. , 1996, Biochimica et biophysica acta.
[23] W. Muller,et al. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. , 1995, Oncogene.
[24] M. Maa,et al. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[25] H. Vogel,et al. Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. , 1994, Genes & development.
[26] Y Wang,et al. A regulatory system for use in gene transfer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] W. Muller,et al. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.
[28] J. DiGiovanni,et al. C57BL/6 mice are resistant to tumor promotion by full thickness skin wounding. , 1993, Carcinogenesis.
[29] G. Staal,et al. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.
[30] Brickell Pm. The p60c-src family of protein-tyrosine kinases: structure, regulation, and function. , 1992 .
[31] J. DiGiovanni,et al. Multistage carcinogenesis in mouse skin. , 1992, Pharmacology & therapeutics.
[32] H. Varmus,et al. Mutations in src homology regions 2 and 3 of activated chicken c-src that result in preferential transformation of mouse or chicken cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[33] Peter K. Vogt,et al. Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice , 1990, Nature.
[34] M. Sporn,et al. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. , 1990, Science.
[35] H. Wanebo,et al. The influence of the surgical wound on local tumor recurrence. , 1989, Surgery.
[36] J. Pipas,et al. pp60c-src activation in human colon carcinoma. , 1989, The Journal of clinical investigation.
[37] M. Okada,et al. Identification of a novel protein tyrosine kinase that phosphorylates pp60c-src and regulates its activity in neonatal rat brain. , 1988, Biochemical and biophysical research communications.
[38] I. Brody. Changes in keratinocyte maturation during wound healing. , 1988, The Journal of investigative dermatology.
[39] M. Sheppard. Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action , 1988 .
[40] J. DiGiovanni,et al. Comparison of the histological changes in the skin of DBA/2 and C57BL/6 mice following exposure to various promoting agents. , 1987, Carcinogenesis.
[41] C. Molloy,et al. Specific alterations in keratin biosynthesis in mouse epidermis in vivo and in explant culture following a single exposure to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. , 1987, Cancer research.
[42] P. Cohen,et al. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. , 1986, The Journal of biological chemistry.
[43] J. Brugge,et al. A normal cell protein similar in structure and function to the avian sarcoma virus transforming gene product. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Brugge,et al. Identification of a transformation-specific antigen induced by an avian sarcoma virus , 1977, Nature.
[45] L. Dunham. Cancer in man at site of prior benign lesion of skin or mucous membrane: a review. , 1972, Cancer research.
[46] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[47] P. Fitzpatrick. [Tumors of the skin]. , 1967, L' Infirmiere canadienne.